The effect of insulin degludec on risk of symptomatic nocturnal hypoglycaemia in adults with type 1 diabetes and high risk of nocturnal severe hypoglycaemia (the HypoDeg trial): study rationale and design

The effect of insulin degludec on risk of symptomatic nocturnal hypoglycaemia in adults with type 1 diabetes and high risk of nocturnal severe hypoglycaemia (the HypoDeg trial): study rationale and design

Abstract Background Hypoglycaemia, especially nocturnal, remains the main limiting factor of achieving good glycaemic control in type 1 diabetes. The effect of first generation long-acting insulin analogues in reducing nocturnal hypoglycaemia is well documented in patient with type 1 diabetes. The e...

Full description

Bibliographic Details
Main Authors: Rikke Mette Agesen, Amra Ciric Alibegovic, Henrik Ullits Andersen, Henning Beck-Nielsen, Peter Gustenhoff, Troels Krarup Hansen, Christoffer Hedetoft, Tonny Jensen, Claus Bogh Juhl, Susanne Søgaard Lerche, Kirsten Nørgaard, Hans-Henrik Parving, Lise Tarnow, Birger Thorsteinsson, Ulrik Pedersen-Bjergaard
Format: Article
Language:English
Published: BMC 2019-07-01
Series:BMC Endocrine Disorders
Subjects:
Type 1 diabetes
Nocturnal hypoglycaemia
Severe hypoglycaemia
Insulin degludec
Insulin glargine
RCT
Online Access:http://link.springer.com/article/10.1186/s12902-019-0408-x

Internet

http://link.springer.com/article/10.1186/s12902-019-0408-x

Similar Items